Targeted Therapy

Targeted Therapy

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor,...
Cancer Journey:
Cancer Type:
We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor,...
Cancer Journey:
Cancer Type:
We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor,...
Cancer Journey:
Cancer Type:
We are excited to share with you more videos from a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor,...
Cancer Journey:
Cancer Type:
We are excited to share with you a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology,...
Cancer Journey:
Cancer Type:

Articles

The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
Cancer Journey:
Cancer Type:
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce James Stevenson, MD.
Cancer Journey:
Cancer Type:
Disease Learning:
Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a...
Cancer Journey:
Cancer Type:
Amidst all of the glowing reports about immunotherapy for lung and many other cancers, it would be understandable for patients and physicians to be tempted to rush toward prioritizing immunotherapy as the first treatment strategy to pursue. In fact ...
Cancer Journey:
Cancer Type:
Among the many novel concepts in managing immunotherapy is the potential for “pseudo-progression”. This unusual phenomenon is when a patient’s scans...
Cancer Journey:
Cancer Type:

Community Forum

Progression after 3 1/2 years on Tarceva. Tissue biopsy showed T790m negative. Any suggestions/experience on next steps? Onc suggesting I move to Afatinib or a Opdivo. PDL1 was tested and is <1%.
Cancer Journey:
Cancer Type:
Has anyone any information on obtaining and using Vaxira, the Cuban drug, for stage 4 advanced NSCLC? Not sure if US citizens can still travel to...
Cancer Journey:
Cancer Type:
My wife has come a long way with Stage IV lung cancer since 2010. She has now developed acquired resistance to Tarceva. Gene sequence of biopsy from...
Cancer Type: